SHANGHAI, July 29, 2015 /PRNewswire/ -- WuXi PharmaTech
(Cayman) Inc. (NYSE: WX), a leading open-access R&D capability
and technology platform company serving the pharmaceutical,
biotechnology and medical device industries, with operations in
China and the United States, today announced that it
will release financial results for the second-quarter of 2015 after the New York Stock
Exchange closes on Thursday, August 13,
2015 (which will be Friday morning, August 14, 2015 Shanghai time). The earnings
release will be available on the investor relations section of the
Company's website at http://www.wuxiapptec.com/.
Following the earnings announcement, WuXi PharmaTech senior
management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong
Kong) on Friday, August 14,
2015, to discuss the second-quarter 2015 financial results
and recent business activities. The conference call may be accessed
by calling:
Mainland
China
|
4001 200 539
|
Hong Kong
|
800 905 927
|
Singapore
|
800 616 3222
|
United
Kingdom
|
0800 015 9725
|
United
States
|
1855 298 3404
|
United States -- New
York (toll)
|
+1 631 5142 526
|
Other countries
(toll)
|
+65 6823 2299
|
Conference
ID
|
2278500
|
A telephone replay will be available two hours after the
call's completion at:
Mainland
China
|
4001 842 240
|
Hong Kong
|
800 966 697
|
Singapore
|
800 616 2127
|
United
Kingdom
|
0800 169 7301
|
United
States
|
1866 846 0868
|
Conference
ID
|
2278500
|
A live webcast of the conference call and replay will be
available in the investor relations section of WuXi PharmaTech's
website at http://www.wuxiapptec.com/.
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading open-access R&D
capability and technology platform company serving the
pharmaceutical, biotechnology, and medical device industries, with
operations in China and the United States. As
a research-driven and customer-focused company, WuXi PharmaTech
provides pharmaceutical, biotechnology, and medical device
companies with a broad and integrated portfolio of laboratory and
manufacturing services throughout the drug and medical device
R&D process. WuXi PharmaTech's services are designed to
help its global partners in shortening the cycle and lowering the
cost of drug and medical device R&D. WuXi is also
building a platform to provide clinical diagnostic services
directly to physicians and their patients globally. The
operating subsidiaries of WuXi PharmaTech are known as WuXi
AppTec. For further information, please visit
http://www.wuxiapptec.com.
For more information, please contact:
Ronald Aldridge
LaVoieHealthScience
+1-617-374-8800 x109
Raldridge@lavoiehealthscience.com
Ron_Aldridge@wuxiapptec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wuxi-pharmatech-schedules-second-quarter-2015-earnings-release-300120802.html
SOURCE WuXi PharmaTech